PharmaCyte Biotech
PMCB
PMCB
24 hedge funds and large institutions have $710K invested in PharmaCyte Biotech in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
24% less capital invested
Capital invested by funds: $934K → $710K (-$224K)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Holders
24
Holding in Top 10
–
Calls
$17K
Puts
$3K
Top Buyers
| 1 | +$12.6K | |
| 2 | +$4.09K | |
| 3 | +$2.66K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.24K |
| 5 |
Renaissance Technologies
New York
|
+$250 |
Top Sellers
| 1 | -$32.3K | |
| 2 | -$20.1K | |
| 3 | -$8.18K | |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$632 |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$250 |
